Shattuck Labs (NASDAQ:STTK) Downgraded by BTIG Research to “Neutral”

Shattuck Labs (NASDAQ:STTKGet Free Report) was downgraded by equities researchers at BTIG Research from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, Marketbeat Ratings reports.

A number of other analysts also recently commented on STTK. Needham & Company LLC reduced their price objective on Shattuck Labs from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, June 14th. HC Wainwright reissued a “buy” rating and issued a $28.00 target price on shares of Shattuck Labs in a report on Wednesday, May 15th.

Check Out Our Latest Stock Analysis on STTK

Shattuck Labs Trading Down 7.8 %

Shares of STTK stock opened at $4.59 on Monday. The stock has a 50 day moving average of $8.59 and a two-hundred day moving average of $8.35. Shattuck Labs has a 12 month low of $1.33 and a 12 month high of $11.76. The company has a market capitalization of $218.26 million, a P/E ratio of -2.38 and a beta of 1.85.

Shattuck Labs (NASDAQ:STTKGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. Shattuck Labs had a negative return on equity of 64.85% and a negative net margin of 3,133.63%. The company had revenue of $1.15 million during the quarter, compared to the consensus estimate of $0.30 million. The company’s quarterly revenue was up 2200.0% compared to the same quarter last year. Sell-side analysts predict that Shattuck Labs will post -1.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Shattuck Labs

Hedge funds have recently modified their holdings of the stock. Cannon Global Investment Management LLC acquired a new position in shares of Shattuck Labs in the 1st quarter worth approximately $91,000. Tower Research Capital LLC TRC raised its holdings in shares of Shattuck Labs by 79.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock worth $97,000 after buying an additional 5,989 shares in the last quarter. Virtu Financial LLC acquired a new stake in Shattuck Labs during the 1st quarter valued at $113,000. Reliant Investment Management LLC acquired a new stake in Shattuck Labs during the 4th quarter valued at $143,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Shattuck Labs during the 1st quarter valued at $174,000. 58.74% of the stock is owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

(Get Free Report)

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

Read More

Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with's FREE daily email newsletter.